1. Academic Validation
  2. Requirement of RORα for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s

Requirement of RORα for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s

  • Hepatology. 2022 May;75(5):1181-1193. doi: 10.1002/hep.32147.
Jiaxi Song 1 2 Hao Song 1 2 Haiming Wei 1 2 Rui Sun 1 2 Zhigang Tian 1 2 3 Hui Peng 1 2
Affiliations

Affiliations

  • 1 Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • 2 Institute of Immunology, University of Science and Technology of China, Hefei, China.
  • 3 Research Unit of NK Cell Study, Chinese Academy of Medical Sciences, Hefei, China.
Abstract

Backgroud and aims: Liver type 1 innate lymphoid cells (ILC1s), also known as liver-resident natural killer (LrNK) cells, comprise a high proportion of total hepatic ILCs. However, factors regulating their maintenance and function remain unclear.

Approach and results: In this study, we found high expression of retinoid-related orphan nuclear receptor alpha (RORα) in LrNK cells/ILC1s. Mice with conditional ablation of retinoid-related orphan nuclear receptor alpha (RORα) in LrNK cells/ILC1s and conventional natural killer (cNK) cells had decreased LrNK cells/ILC1s but normal numbers of cNK cells. RORα-deficient LrNK cells/ILC1s displayed increased Apoptosis and significantly altered transcriptional profile. Using a murine model of colorectal Cancer liver metastasis, we found that RORα conditional deficiency resulted in more aggressive liver tumor progression and impaired effector molecule expression in LrNK cells/ILC1s. Consequently, treatment with the RORα agonist efficiently limited liver metastases and promoted effector molecule expression of LrNK cells/ILC1s.

Conclusions: This study reveals a role of RORα in LrNK cell/ILC1 maintenance and function, providing insights into the harnessing of LrNK cell/ILC1 activity in the treatment of liver Cancer.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-14422
    99.46%, RORα/RORγ Agonist
    ROR